Soil carbon sequestration and stocks: short-term impact of maize succession to cover crops in Southern Brazil Inceptisol

Aim of study: To evaluate soil organic carbon (SOC) sequestration and stock over the succession of maize to winter cover crops under a short-term no-tillage system.Area of study: A subtropical area in Southern Brazil.Material and methods: The experiment was implemented in 2013. The treatments were: seven winter cover crops single cultivated (white-oats, black-oats, annual-ryegrass, canola, vetch, fodder-radish and red-clover); an intercropping (black-oats + vetch); and a fallow, with maize in succession. Soil samples were collected after four years of experimentation, up to 0.60 m depth, for SOC determination.Main results: SOC stocks at 0-0.6 m depth ranged from 96.2 to 107.8 t/ha. The SOC stocks (0-0.60 m depth) were higher under vetch and black-oats, with an expressive increase of 23 and 20% for C stocks in the 0.45-0.60 m layer, compared to fallow. Thus, SOC sequestration rates (0-0.60 m depth), with vetch and black oats, were 1.68 and 0.93 t/ha·yr, respectively.Research highlights: The establishment of a high-quality and high C input cover crops in the winter, as vetch or black-oats in succession to maize, are able to increase SOC stocks, even in the short term.

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN